DrugDashboards

Omnipaque

Iohexol · IOHEXOL 350 mg/mL · Injection, Solution · Intra-Articular; Intravascular; Intravenous; Oral · GE Healthcare Inc.

NDC 00407-1414-76 · 10 BOTTLE, GLASS in 1 BOX / 125 mL in 1 BOTTLE, GLASS · NDA · View full market →

The short version

4 companies supply this market — a reasonable cushion if one runs into trouble. 2 Class II recalls hit this product in the past year (GE Healthcare Ireland Limited).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Medicare Part B (ASP)

Payment limit per 1 ML
$0.155
HCPCS Q9967 · Jul 1, 2026 quarter · typically ASP + 6%

Medicaid spend (2025)

$34,722
1,231 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
NDA018956
TE code
AP
Approval date
Dec 26, 1985
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

  • Class II · OngoingMar 24, 2026
    GE Healthcare Ireland Limited — Presence of particulate matter
  • Class II · OngoingMar 24, 2026
    GE Healthcare Ireland Limited — Presence of particulate matter
  • Class II · TerminatedOct 29, 2018
    GE Healthcare Inc. Life Sciences — Defective Container: vial defect was identified that could potentially impact the container closure and result in a lack of sterility assurance and/or the potential for glass particles.

Manufacturers of Iohexol (Injection, Solution)

LabelerStrengthFirst seenLast seen
Amneal Pharmaceuticals Private LimitedIOHEXOL 350 mg/mLJul 22, 2026Sep 3, 2026
GE HealthcareIOHEXOL 300 mg/mLJul 15, 2026Sep 2, 2026
GE HealthcareIOHEXOL 350 mg/mLJul 15, 2026Sep 2, 2026
GE Healthcare Inc.IOHEXOL 300 mg/mLJul 15, 2026Sep 2, 2026
GE Healthcare Inc.IOHEXOL 350 mg/mLJul 15, 2026Sep 2, 2026
GE Healthcare Inc.IOHEXOL 180 mg/mLJul 15, 2026Sep 2, 2026
GE Healthcare Inc.IOHEXOL 240 mg/mLJul 15, 2026Sep 2, 2026
GE Healthcare Inc.IOHEXOL 140 mg/mLJul 15, 2026Sep 2, 2026
Medical Purchasing Solutions, LLCIOHEXOL 240 mg/mLJul 15, 2026Sep 2, 2026
Medical Purchasing Solutions, LLCIOHEXOL 300 mg/mLJul 15, 2026Sep 2, 2026
Amneal Pharmaceuticals Private LimitedIOHEXOL 300 mg/mLJul 15, 2026Aug 31, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Omnipaque — NDC 00407-1414-76," retrieved September 3, 2026, https://drugdashboards.com/drug/00407141476.

Free to cite with attribution — see how the data is put together.